Alzheimer Clinical Trials in Tampa, Florida
24 recruitingTampa, Florida
Showing 1–20 of 24 trials
Recruiting
Phase 2Phase 3
ACP-204 in Adults With Alzheimer's Disease Psychosis
Alzheimer's Disease Psychosis
ACADIA Pharmaceuticals Inc.1,074 enrolled148 locationsNCT06159673
Recruiting
Phase 2
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
Agitation Associated With Alzheimer's Dementia
Intra-Cellular Therapies, Inc.320 enrolled70 locationsNCT06651567
Recruiting
Phase 3
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
Alzheimers Disease
Hoffmann-La Roche80,000 enrolled211 locationsNCT07177352
Recruiting
Phase 2
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
Psychosis Associated With Alzheimer's Disease
Intra-Cellular Therapies, Inc.370 enrolled65 locationsNCT06540833
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
Alzheimer s Disease
Bristol-Myers Squibb586 enrolled126 locationsNCT06976203
Recruiting
Phase 3
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
Psychosis Associated With Alzheimer's Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company410 enrolled129 locationsNCT05511363
Recruiting
Phase 3
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Alzheimer Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company406 enrolled292 locationsNCT06585787
Recruiting
Phase 2
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
Early Alzheimer's Disease
Merck Sharp & Dohme LLC340 enrolled79 locationsNCT07033494
Recruiting
Phase 3
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Psychosis Associated With Alzheimer's Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company1,000 enrolled429 locationsNCT05980949
Recruiting
Phase 3
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
Alzheimers Disease
Hoffmann-La Roche800 enrolled143 locationsNCT07169578
Recruiting
Phase 3
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
Alzheimer DiseaseAgitation
Bristol-Myers Squibb650 enrolled256 locationsNCT06937229
Recruiting
Phase 1
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
HealthyAlzheimer Disease
Eli Lilly and Company128 enrolled13 locationsNCT06657768
Recruiting
Phase 2
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
Alzheimer DiseaseAgitation
Celgene120 enrolled53 locationsNCT06808984
Recruiting
Phase 2
Clinical Trial on Agitation in Alzheimer's Dementia
Alzheimer DiseaseAggressionAgitation,Psychomotor+2 more
IGC Pharma, LLC164 enrolled31 locationsNCT05543681
Recruiting
Phase 2
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
Psychosis Associated With Alzheimer's Disease
MapLight Therapeutics300 enrolled40 locationsNCT06887192
Recruiting
Phase 3
A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD
Early Alzheimers Disease
Annovis Bio Inc.760 enrolled81 locationsNCT06709014
Recruiting
Not Applicable
Palliative Care Education in Assisted Living for Dementia Care Providers (PCEAL-DCP)
End of LifePatient ParticipationAlzheimer Disease+3 more
University of South Florida792 enrolled2 locationsNCT06722352
Recruiting
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
Memory DisordersMild Cognitive ImpairmentMemory Impairment+3 more
GAP Innovations, PBC1,200 enrolled26 locationsNCT06584357
Recruiting
Not Applicable
ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease
Alzheimer Disease
InSightec50 enrolled10 locationsNCT03671889
Recruiting
Phase 3
Preventing Alzheimer's With Cognitive Training
Age-related Cognitive DeclineAlzheimer's Disease and Related Dementias
University of South Florida7,600 enrolled7 locationsNCT03848312